SML0148
Imidapril hydrochloride
≥98% (HPLC)
同義詞:
(4S)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid hydrochloride, Novaloc, TA 6366, Tanapril
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C20H27N3O6 · HCl
CAS號碼:
分子量：:
441.91
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D -50 to -70° in ethanol (c=0.5)
顏色
white to tan
溶解度
H2O: ≥5 mg/mL
起源
Trinity Pharma Solutions
儲存溫度
−20°C
SMILES 字串
Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O
InChI
1S/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1
InChI 密鑰
LSLQGMMMRMDXHN-GEUPQXMHSA-N
一般說明
Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.
應用
Imidapril hydrochloride may be used to test its effect on pharyngeal and laryngeal muscle to treat impaired swallowing.
Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.
生化／生理作用
Imidapril hydrochloride is a long-acting inhibitor of angiotensin converting enzyme used in the treatment of hypertension, congestive heart failure and diabetic nephropathy. It restores decreased airway sensation and bladder sensation in patients with multiple sclerosis.
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.
特點和優勢
This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Trinity Pharma Solutions. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Yosuke Takeda et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 33(9), 965-973 (2010-07-29)
We and others recently reported that long-term Rho-kinase inhibition has renoprotective effects. This study was designed to compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (imidapril), a Rho-kinase inhibitor (fasudil) and a combination of them both on renal interstitial
Kazuhide Ogino et al.
Circulation journal : official journal of the Japanese Circulation Society, 74(11), 2346-2352 (2010-09-10)
Angiotensin II and insulin resistance (IR) have clinical implications in the pathophysiology of chronic heart failure (CHF). However, it is still unclear whether the combination of an angiotensin-receptor blocker and angiotensin-converting enzyme inhibitor (ACEI) improves IR in CHF patients who
Ryo Watanabe et al.
Journal of cardiovascular pharmacology, 59(4), 323-330 (2011-12-02)
Angiotensin converting enzyme inhibitors have been used clinically to prevent myocardial infarction (MI). The angiotensin converting enzyme inhibitors attenuated ventricular remodeling and improved cardiac function by inhibition of matrix metalloproteinases after MI. Although the effect is thought to be a
Hiromichi Yoshida et al.
Respiration; international review of thoracic diseases, 72(4), 423-426 (2005-08-10)
We describe an unusual case of a patient with eosinophilic pleurisy associated with long-term administration of imidapril, an angiotensin-converting enzyme inhibitor (ACEI). An 81-year-old woman who had been given imidapril for the treatment of essential hypertension was admitted to our
Tetsuya Matsumoto et al.
Hypertension (Dallas, Tex. : 1979), 56(3), 364-368 (2010-07-08)
The renin-angiotensin system regulates the vascular fibrinolytic balance. In the human forearm vasculature, angiotensin-converting enzyme (ACE) inhibitors (ACE-Is) increase the release of t-PA through endogenous bradykinin. We tested the hypothesis that ACE inhibition and sex modulate the endogenous coronary release
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務